Rapid Acting Antidepressants

Ronald Duman is at Yale University School of Medicine, CT, USA

Part I - Neurobiology of ketamine effects
Effects of ketamine and other rapidly acting antidepressants on hippocampal excitatory and inhibitory transmission
Allie J. Widman and Lori L. McMahon
Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition
Bernhard Luscher, Mengyang Feng and Sarah J. Jefferson
The role of eEF2 kinase in the rapid antidepressant actions of ketamine
Kanzo Suzuki and Lisa M. MonteggiaPart II - The rapid therapeutic effects of ketamine
Clinical overview of NMDA-R antagonists and clinical practice
Pasha A. Davoudian and Samuel T. Wilkinson
Ketamine for depression clinical issues
Syed Z. Iqbal and Sanjay J. Mathew
Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence
Lynnette A. Averill, Samar Fouda, James W. Murrough andChadi G. Abdallah
Neurobiological biomarkers of response to ketamine
Bashkim Kadriu, Elizabeth D. Ballard, Ioline D. Henter, Stephen Murata, Nimesha Gerlus and Carlos A. Zarate Jr
Relapse prevention in treatment resistant major depressive disorder with rapid-acting antidepressants
Jaskaran B. Singh, Maggie Fedgchin, Ella J. Daly and Wayne C. Drevets
The emergence of ketamine as a novel treatment for posttraumatic stress disorder
Adriana Feder, Sarah B. Rutter, Daniela Schille and Dennis S. CharneyPart III - Novel rapid-acting antidepressant mechanisms related to ketamine
mGlu2/3 receptor as a novel target for rapid acting antidepressants
Shigeyuki Chaki
Involvement of muscarinic receptor mechanisms in antidepressant drug action
Jeffrey M. Witkin, Jodi L. Smith, Lalit K. Golani, Emily A. Brooks and Anna E. Martin
The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions
Wayne C. Drevets, Anindya Bhattacharya and Maura L. Furey